Abstract：
OBJECTIVE: We report the results of an international consensus on hyperthermic intraperitoneal chemotherapy (HIPEC) regimens for epithelial ovarian cancer (EOC) performed with the following goals: To define the indications for HIPEC To identify the most suitable HIPEC regimens for each indication in EOC To identify areas of future research on HIPEC To provide recommendations for some aspects of perioperative care for HIPEC METHODS: The Delphi technique was used with two rounds of voting. There were three categories of questions: evidence-based recommendations [using the Grades of Recommendation, Assessment, Development, and Evaluation (GRADE) system with the patient, intervention, comparator, and outcome (PICO) method], an opinion survey, and research recommendations.
RESULTS: Seventy-three (67.5%) of 108 invited experts responded in round I, and 68 (62.9%) in round II. Consensus was achieved for 34/38 (94.7%) questions. However, a strong positive consensus that would lead to inclusion in routine care was reached for only 6/38 (15.7%) questions. HIPEC in addition to interval cytoreductive surgery (CRS) received a strong positive recommendation that merits inclusion in routine care. Single-agent cisplatin was the only drug recommended for routine care, and OVHIPEC-1 was the most preferred regimen. The panel recommended performing HIPEC for a minimum of 60 min with a recommended minimum intraabdominal temperature of 41°C. Nephroprotection with sodium thiosulfate should be used for cisplatin HIPEC.
CONCLUSIONS: The results of this consensus should guide clinical decisions on indications of HIPEC and the choice and various parameters of HIPEC regimens and could fill current knowledge gaps. These outcomes should be the basis for designing future clinical trials on HIPEC in EOC.
RESULTS: Seventy-three (67.5%) of 108 invited experts responded in round I, and 68 (62.9%) in round II. Consensus was achieved for 34/38 (94.7%) questions. However, a strong positive consensus that would lead to inclusion in routine care was reached for only 6/38 (15.7%) questions. HIPEC in addition to interval cytoreductive surgery (CRS) received a strong positive recommendation that merits inclusion in routine care. Single-agent cisplatin was the only drug recommended for routine care, and OVHIPEC-1 was the most preferred regimen. The panel recommended performing HIPEC for a minimum of 60 min with a recommended minimum intraabdominal temperature of 41°C. Nephroprotection with sodium thiosulfate should be used for cisplatin HIPEC.
CONCLUSIONS: The results of this consensus should guide clinical decisions on indications of HIPEC and the choice and various parameters of HIPEC regimens and could fill current knowledge gaps. These outcomes should be the basis for designing future clinical trials on HIPEC in EOC.
摘要：
目的：我们报告了上皮性卵巢癌（EOC）腹腔热化疗（HIPEC）方案的国际共识结果，其目标如下：定义HIPEC的适应症确定EOC中每个适应症的最合适的HIPEC方案确定HIPEC的未来研究领域为HIPEC方法的围手术期护理的某些方面提供建议：使用了两轮投票技术。有三类问题:基于证据的建议[使用建议等级，评估,发展,与患者的评估（等级）系统，干预，比较器,和结果(PICO)方法]，意见调查,和研究建议。
结果：108位受邀专家中有73位（67.5％）在第一轮中做出了回应，第二轮为68人(62.9%)。对34/38（94.7％）的问题达成了共识。然而,只有6/38(15.7%)的问题达成了将导致纳入常规护理的强烈积极共识.除了间隔细胞减灭术（CRS）外，HIPEC还获得了强烈的积极建议，值得纳入常规护理。单药顺铂是唯一推荐用于常规护理的药物，OVHIPEC-1是最优选的方案.小组建议执行HIPEC至少60分钟，建议最低腹内温度为41°C。顺铂HIPEC应使用硫代硫酸钠的肾脏保护。
结论：这一共识的结果应指导HIPEC适应症的临床决策以及HIPEC方案的选择和各种参数，并可以填补目前的知识空白。这些结果应该是设计未来EOC中HIPEC临床试验的基础。
结果：108位受邀专家中有73位（67.5％）在第一轮中做出了回应，第二轮为68人(62.9%)。对34/38（94.7％）的问题达成了共识。然而,只有6/38(15.7%)的问题达成了将导致纳入常规护理的强烈积极共识.除了间隔细胞减灭术（CRS）外，HIPEC还获得了强烈的积极建议，值得纳入常规护理。单药顺铂是唯一推荐用于常规护理的药物，OVHIPEC-1是最优选的方案.小组建议执行HIPEC至少60分钟，建议最低腹内温度为41°C。顺铂HIPEC应使用硫代硫酸钠的肾脏保护。
结论：这一共识的结果应指导HIPEC适应症的临床决策以及HIPEC方案的选择和各种参数，并可以填补目前的知识空白。这些结果应该是设计未来EOC中HIPEC临床试验的基础。
